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Thus far few clinical trials have been performed with the aim of
treating patients affected by endometrial cancer with luteinizing
hormone-releasing hormone (LHRH) analogues. Moreover, from
such studies often conflicting results have emerged: in fact, while
Gallagher (Gallagher et al, 1991; Jeyarajah et al, 1996), De Vriese
(De Vriese and Bonte, 1993) and Lhommé (Lhommé et al, 1999)
documented clinical responses ranging from 8.7% (2 cases out of
23) to 57% (4 cases out of 7), Covens (Covens et al, 1997) and
Markman (Markman et al, 1997) did not observe any response. In
any case, all the trials were performed in patients affected by
recurrent or metastatic endometrial cancer, while a study on the
use of LHRH analogues as a primary treatment for this type of
cancer is currently lacking. Moreover, no data on the LHRH
receptor status was reported in the above-cited studies. 
In this study, we report the case of a patient affected by endome-
trial cancer and treated primarily with LHRH analogue, the
surgical approach being unfeasible due to her compromised health.
The therapy was carried on for more than 6 years, and no progres-
sion of the disease was observed. During this period, some histo-
logical and immunohistochemical evaluations of the tumour,
including morphology, grading, proliferating index and apoptotic
power, were performed. Moreover, the expression of m-RNA for
LHRH receptors was determined. 
The results showed a discrepancy between the biological
features of the tumour (such as increase of grading and prolifer-
ating capacity, associated with a failure in the reparative process)
and its clinical appearance (lack of local invasion or metastatic
lesions), giving new evidence of the favourable impact of LHRH
analogue treatment in patients affected by endometrial cancer. 
THE CASE 
The patient BB, aged 74, para 2, with menopausal transition at 60
years, came to our care in November 1999, being previously cared
for by a private gynaecologist. 
She was affected by cerebellar ataxia and had had several
episodes of myocardial infarction. In 1988 she underwent a curet-
tage of the uterine cavity for metrorrhagia, with a histological
diagnosis of atypical endometrial hyperplasia. Afterwards, the
patient was given progesterone at high doses for 6 months and
underwent a second curettage with a diagnosis of simple hyper-
plasia in cystic regression. In the absence of symptoms, the
patient abandoned the follow up as well as the therapy. 5 years
later, in February 1994, the patient had another episode of metror-
rhagia: a curettage of the cavity was performed, giving rise to the
diagnosis of endometrial adenocarcinoma. A surgical treatment
could not be applied at that time due to the patient’s severely
compromised health conditions; therefore she was treated with
LHRH analogues. The treatment consisted of monthly injections
of 3.75 mg of leuprolide (Enantone depot 3.75 mg, Takeda Italia,
Rome, Italy); the therapy was regularly administered until the time
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the patient experienced an episode of bleeding: a curettage was
performed and the diagnosis of endometrial cancer confirmed. 
At the time of her first admission at our clinic, the patient’s
weight and height were 92 kg and 168 cm, respectively, and blood
pressure values 155/85 mmHg. Baseline blood parameters were in
the normal range. Head and chest X-ray scans showed normal
figures. The transabdominal and transvaginal ultrasound examina-
tion of the pelvis revealed a uterus bigger than expected for the
menopausal period (92 ´ 45 ´ 88 cm), with thickened and non-
homogeneous endometrial patterns (18 mm). The ovaries were in
the normal dimensional range, and no fluid was present in the
Douglas pouch. The CT scan of upper and lower abdominal quad-
rants confirmed the endometrial thickening and demonstrated no
involvement of aortic and iliac lymph nodes and no myometrial
infiltration. A curettage of the uterine cavity was performed: a
specimen of the tumour was placed in buffered formaline for
pathological evaluation and another, collected in sterile condi-
tions, was frozen and stored in liquid nitrogen for molecular
biology evaluations (RT-PCR assay). 
Since all the endometrial specimens arising from previous
curettages of the cavity had been referred to the Pathology
Department of our University, the pathologist (GLT) was able to
reconsider all those slides at the same time, along with the
endometrial sample obtained at the time of admission to our
Clinic. Moreover, an immunohistochemical study for oestrogen
and progesterone receptors, proliferative index (MIB-1), p53, 
bcl-2, E-cadherin and c-erb-2 was performed on all endometrial
samples collected so far. An informed consent from the patient for
this study was obtained. 
Pictures of all endometrial specimens collected from the patient,
from the time of first curettage in 1988 onwards, are shown 
in Figure 1. All previous histopathological diagnoses were
confirmed; moreover, the cancer was referred to as usual
(endometroid) carcinoma. As to cancer grading, a high-grade
differentiation (GI) was observed in one of the first sample (Figure
1C), whereas an intermediate-grade differentiation (G2) was found
in specimens collected later, as shown in Figures 1D and 1E. 
An immunohistochemical study on several consecutive sections
of each endometrial specimen collected was performed, as previ-
ously reported (Noci et al, 2000). Several different primary anti-
bodies were used: monoclonal antibody 1D5 raised against human
oestrogen receptor (1:30 dilution, Bio-Genex, San Ramon, CA,
USA); monoclonal antibody 1A6 raised against human proges-
terone receptor (1:50 dilution, Bio-Genex); monoclonal antibody
MIB-1 raised against nuclear antigen Ki-67 (1:60 dilution,
IMMUNOTECH, Marseilles); a murine monoclonal IgG2 anti-
body DO-7 raised against human p53 (1:40 dilution, DAKO A/S,
Denmark), which reacts with wild-type and mutant p53 protein; a
murine monoclonal (clone 124, IgG1) anti-human bcl-2 antibody
(1:20 dilution, DAKO). C-erb-2 protein expression was investi-
gated with the specific monoclonal antibody TAB 250 (1:20 dilu-
tion, ZYMED Laboratories, San Francisco, CA). For E-cadherin
detection, the monoclonal antibody HECD-1 (ZYMED) was used
at 1:800 dilution. Negative control experiments were performed
by replacing the primary antibodies with non-immune mouse
serum at an equivalent protein concentration. The positivity of
oestrogen and progesterone receptors, MIB-1, p53, bcl-2, E-
cadherin and c-erb-2 were evaluated by estimating the fraction of
positive cells on the total number of neoplastic cells, in 10 separate
fields at 40 ´ 10 HPF. The immunostaining was scored as 0(5%),
1(6–10%), 2(11–50%), 3(> 50%), according to Taskin (Taskin et
al, 1997). The results of the immunohistochemical study are
reported in Table 1. 
Reverse transcription-polymerase chain reaction (RT-PCR)
amplification studies, performed as previously reported (Noci 
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Figure 1 Histological patterns of endometrial samples collected at different times: (A) hyperplastic mild hyperplasia (1988); (B) hyperplasia in regression,
after 6 months of progesterone therapy (1989); (C) high-grade differentiation (G1) endometrial adenocarcinoma, referred as ordinary (usual) carcinoma, at her
first diagnosis (1994); (D) intermediate-grade differentiation (G2) endometrial adenocarcinoma, after 2 years of therapy with LHRH analogues (1996);
(E) intermediate-grade differentiation (G2) endometrial adenocarcinoma, during last admission, after 69 months of therapy with LHRH-analogues (1999) et al, 2000) were performed only on the endometrial specimen
collected in our clinic, since a freshly collected sample was
required. The endometrial specimen analysed was shown to be
positive for LHRH receptor mRNA (not shown). 
DISCUSSION 
The main comment for the case here presented arises from the
behaviour of this tumour, which was retrospectively studied for
more than 6 years. During this time interval, a discrepancy
between the biology of the tumour and its clinical appearance was
observed. In fact, as far as the biology of the tumour is concerned,
there was an increase of both tumour grading (from G1 to G2) and
cancer-proliferating capacity (MIB-1 from Taskin score 1 to 3),
and a failure in the reparative process (appearance of mutant form
of p53, and reduced expression of both bcl-2 and c-erb-2) (Table
1). On the whole, all these findings would suggest a progression of
the cancer. Conversely, the clinical course of the disease, as
revealed by all the investigations performed during the admission
of the patient to our clinic, was not associated either with local
invasion or metastatic lesions. We propose here that this discrep-
ancy could be explained by and related to the maintenance of high
levels of E-cadherin expression (Taskin score 3: see Table 1) along
with time. 
E-cadherins are members of a family of transmembrane glyco-
proteins mediating cell–cell adhesion. They are expressed by
epithelial cells and are believed to play a key role in cellular organ-
isation, tissue remodelling and in mediating extracellular
signalling (Nelson et al, 1990; Magee and Buxton, 1991). It has
been proposed that loss of E-cadherin expression leads to dissocia-
tion of tumour cells and promotes invasion (Shimoyama and
Hirohashi, 1991; Shimoyama et al, 1992; Oda et al, 1993).
Consistently, E-cadherin expression has been shown to be
inversely correlated with both depth of myometrial invasion and
paraaortic lymph node metastasis in endometrial cancers (Sakuragi
et al, 1994; Fujimoto et al, 1998). In the case presented here, 
E-cadherin expression was maintained for a period of several years
at very high levels (Taskin score 3); therefore, the documented
lack of myometrial invasion and node metastasis might be
explained by this feature of the tumour. Moreover, the aforemen-
tioned papers (Sakuragi et al, 1994; Fujimoto et al, 1998) reported
that E-cadherin expression decreased with the loss of differentia-
tion of the endometrial cancer. Conversely, in our case, the 
E-cadherin expression remained constant and at high levels
throughout time, despite the increase in tumour grading, and
proliferative index as well as the loss of reparative process. Thus,
the discrepancy between biological and clinical features of the
tumour here studied could be associated with the discrepancy, at
the histopathological levels, between E-cadherin expression and
all the other parameters investigated. 
We have no clear-cut explanations for this discrepancy, but
some hypotheses can be proposed: as a first hypothesis, the poss-
ibility exists of the serlendipity of this result, with the above
reported feature being a peculiarity of this single case. A second
explanation relies on the fact that in vitro studies reported that 
E-cadherin expression was significantly suppressed by oestrogens,
a suppression antagonized by progesterone (Fujimoto et al, 1996).
In the post-menopausal period, the ovary is no longer a source of
estrogens; conversely, oestrogens derive from extraglandular
conversion of androgens, mainly at the fat tissue level (Grodin et
al, 1973). The BMI in our patient is 32.6, so that the patient can be
classified as an obese woman. In this woman, we can easily
suppose a high, chronic conversion of androgens to oestrogens at
the fat tissue level. Hilum cells of the post-menopausal ovary
produce testosterone and D4-androstenedione; the function of
these cells is poorly known but is influenced, probably, by
gonadotropins, and especially by LH (Yen and Jaffe, 1978). In our
case, the patient had been desensitized by LHRH analogues for
more than 5 years; so, the LH pituitary production and the ovarian
androgen secretion had been profoundly suppressed. Therefore, it
is tempting to deduce that the woman experienced a reduction in
the production rate of oestrogens, which can eventually account
for the lack of reduced expression of E-cadherin. 
The third explanation relies on the fact that, in this case, the
tumour expressed mRNA for LHRH receptors. Therefore, it is
reasonable that the chronic treatment with LHRH analogues might
have exerted a direct or indirect effect on E-cadherin expression at
the endometrial tissue level. No current data are available at the
moment supporting or refusing this hypothesis. 
In conclusion, although further studies are necessary, it is the
authors’ opinion that this case of endometrial cancer may provide
new intriguing implications on the clinical effects of LHRH
analogues in the treatment of patients affected by endometrial
cancer. 
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Table 1 Immunohistochemical results in endometrial specimens collected at different times 
Date MIB-1 p53 ER PR bcl-2 E-cadherin c-erb-2 
GI str GI str GI str
1988 0 0 3 0 3 1 3 2 3 3 
1989 0 0 3 3 2 2 0 2 3 3 
1994 1 0 3 1 3 1 3 1 3 3 
1996 3 2 3 1 3 1 2 1 3 0 
1999 3 2 3 0 3 0 0 3 3 0 
ER = oestrogen receptor; GI = endometrial glands; PR = progesterone receptor; str = endometrial stromal cells. 
All values are expressed as Taskin score (see text) as following: 0 (≤ 5%); 1 (6–10%); 2 (11–50%); 3 (>50%). REFERENCES 
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